Friday, December 6, 2013, New Orleans, LA, 6:00 PM – 9:00 PM (Central Time)

Consensus or Controversy? — Live: Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Multiple Myeloma (Part 2 of a 2-Part Series)

A Friday Satellite Symposium preceding the 55th ASH Annual Meeting

Hilton New Orleans Riverside Hotel
Two Poydras Street
New Orleans, LA 70140
Hotel Phone: (504) 561-0500

6:00 PM – 6:30 PM (Central Time) — Registration and Dinner
6:30 PM – 9:00 PM (Central Time) — Educational Meeting

Meeting Room: Grand Ballroom (1st Floor)

There is no registration fee for this event. However, registration is limited to clinicians in practice. Preregistration is advised as seating is limited.


William I Bensinger, MD
Professor of Medicine
University of Washington
Member, Fred Hutchinson
Cancer Research Center
Director, Autologous Stem Cell Transplant Program
Seattle, Washington

Meletios A Dimopoulos, MD
Chairman, Department of Medical
University of Athens School
of Medicine
Athens, Greece

Amrita Krishnan, MD
Director, Multiple Myeloma Program
City of Hope Cancer Center
Duarte, California

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

A Keith Stewart, MBChB
Dean for Research
Mayo Clinic in Arizona
Consultant, Division of
Vasek and Anna Maria Polak
Professorship in Cancer Research
Scottsdale, Arizona


Neil Love, MD
Research To Practice
Miami, Florida

Module 1: Up-Front Treatment for Transplant-Eligible Patients — Dr Krishnan

Key Issues

  • What is the evidence that administration of a 3-drug regimen results in better long-term outcomes than a 2-drug regimen in this setting?
  • When using bortezomib as part of an up-front treatment regimen, do you initially use subcutaneous or intravenous administration? A twice-weekly or a weekly schedule? Does your approach change for a patient with renal failure or the presence of major symptomatology?

Module 2: Maintenance/Consolidation Therapy and Impact of Adverse Cytogenetics
— Dr Stewart

Key Issues

  • What is the clinical trial evidence for post-transplant maintenance and consolidation therapy for patients with normal and high-risk cytogenetics?

Module 3: Carfilzomib and Other Novel Proteasome Inhibitors — Dr Bensinger

Key Issues

  • What is the evidence — using indirect comparison — for the efficacy and tolerability of carfilzomib versus bortezomib in the up-front treatment setting?
  • What is the frequency of carfilzomib-associated cardiopulmonary toxicity, and what are the clinical implications?
  • What other novel proteasome inhibitors (eg, ixazomib, marizomib, oprozomib) are currently being evaluated in clinical trials?

Module 4: Pomalidomide and Other Emerging Agents — Dr Dimopoulos

Key Issues

  • What is known about the relative efficacy and tolerability of pomalidomide versus thalidomide and lenalidomide?
  • What agents are reasonable to combine with pomalidomide in the relapsed/refractory setting?
  • What other novel agents under investigation for MM (eg, elotuzumab, daratumumab) do you believe will be available to patients in the future?

Module 5: Smoldering Myeloma; Bone-Directed Therapy — Dr Raje

Key Issues

  • What is known about the natural history and potential interventions for high- and low-risk smoldering myeloma?
  • What is your usual bone-targeted treatment for a younger, otherwise healthy patient with MM and lytic lesions? For how long do you continue this treatment? What if the patient had no bone involvement?

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives:

Upon completion of this activity, participants should be able to:

  • Appraise recent data on therapeutic advances and changing practice standards in MM, and integrate this information, when appropriate, into current clinical care.
  • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
  • Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
  • Develop a risk-adapted treatment plan for patients with smoldering myeloma, considering the roles of observation and active treatment.
  • Recall new data with investigational agents demonstrating promising activity in MM.
  • Assess the ongoing clinical trials evaluating innovative investigational approaches for MM, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of this activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.

This live activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.

Hilton New Orleans Riverside Hotel
Two Poydras Street
New Orleans, LA 70140
Hotel Phone: (504) 561-0500

Meeting Room: Grand Ballroom (1st Floor)

The Hilton New Orleans Riverside hotel is located 2 blocks from the Ernest N Morial Convention Center, where the ASH Annual Meeting is taking place.

Thank you for your interest our program. At this time, pre-registration is closed for this eventOnsite registration will be open starting at 6:00 PM (Eastern Time) on Friday, December 6. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (1st Floor) at the Hilton New Orleans Riverside Hotel (Two Poydras Street, New Orleans, LA 70140). 

If seats become available for the program, we will accept new registrations on a first come, first serve basis. Please note onsite registration does not guarantee participation in the session or meal service and seating is limited to clinicians in practice.

If you have any questions, please feel free to contact us via email at or call (800) 233-6153.

This educational session has been approved by ASH as part of the Friday Satellite Symposia educational schedule and registration for this event is independent of registration for the ASH conference.